Roivant's experimental pulmonary hypertension drug meets Phase 2 goals
Roivant announced that its experimental drug mosliciguat achieved the primary endpoint in a 16‑week Phase 2 trial for pulmonary hypertension, a serious lung condition.
The study showed a 56% reduction in pulmonary vascular resistance versus placebo, indicating a substantial improvement in blood flow from the heart to the lungs.
Secondary measures also reached significance, with patients walking 35 meters farther in six minutes and a 53% drop in the heart‑failure biomarker NT‑proBNP compared with placebo.
The positive data could open a new therapeutic approach for the disease and strengthen Roivant’s pipeline and financial outlook.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Roivant lung disease drug hits mid-stage study goals”
read at STAT ↗
comments(0)
5-min edit window · permanent after that